AU1101901A - Human fgf-20 gene and gene expression products - Google Patents

Human fgf-20 gene and gene expression products

Info

Publication number
AU1101901A
AU1101901A AU11019/01A AU1101901A AU1101901A AU 1101901 A AU1101901 A AU 1101901A AU 11019/01 A AU11019/01 A AU 11019/01A AU 1101901 A AU1101901 A AU 1101901A AU 1101901 A AU1101901 A AU 1101901A
Authority
AU
Australia
Prior art keywords
gene
expression products
human fgf
gene expression
fgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11019/01A
Other languages
English (en)
Inventor
Nobuyuki Itoh
W. Michael Kavanaugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University
Novartis Vaccines and Diagnostics Inc
Original Assignee
Kyoto University
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University, Chiron Corp filed Critical Kyoto University
Publication of AU1101901A publication Critical patent/AU1101901A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU11019/01A 1999-10-22 2000-10-20 Human fgf-20 gene and gene expression products Abandoned AU1101901A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16116299P 1999-10-22 1999-10-22
US60161162 1999-10-22
US18785600P 2000-03-08 2000-03-08
US60187856 2000-03-08
PCT/US2000/029237 WO2001031008A2 (en) 1999-10-22 2000-10-20 Human and rat fgf-20 genes and gene expression products

Publications (1)

Publication Number Publication Date
AU1101901A true AU1101901A (en) 2001-05-08

Family

ID=26857561

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11019/01A Abandoned AU1101901A (en) 1999-10-22 2000-10-20 Human fgf-20 gene and gene expression products

Country Status (5)

Country Link
EP (1) EP1224283A2 (enExample)
JP (1) JP2003512841A (enExample)
AU (1) AU1101901A (enExample)
CA (1) CA2388637A1 (enExample)
WO (1) WO2001031008A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056885B1 (en) 1999-07-27 2006-06-06 Curagen Corporation Fibroblast growth factor and nucleic acids encoding same
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
WO2001068854A2 (en) * 2000-03-13 2001-09-20 Amgen, Inc. Fibroblast growth factor-like molecules and uses thereof
GB2365869A (en) * 2000-05-30 2002-02-27 Smithkline Beecham Corp SbgFGF-9a polynucleotides and polypeptides
AU2001262934A1 (en) * 2000-06-01 2001-12-11 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
JP2004502418A (ja) * 2000-07-03 2004-01-29 キュラジェン　コーポレイション 新規の線維芽細胞増殖因子およびそれをコードする核酸
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
US20020151496A1 (en) * 2000-12-08 2002-10-17 Bringmann Peter W. Novel fibroblast growth factors
JP2005500035A (ja) * 2001-06-15 2005-01-06 キュラジェン コーポレイション 新規線維芽細胞成長因子およびそれをコード化する核酸
WO2004105787A1 (en) * 2003-05-28 2004-12-09 The University Of Kyoto Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2367375A1 (en) * 1999-03-15 2000-09-21 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US7056885B1 (en) * 1999-07-27 2006-06-06 Curagen Corporation Fibroblast growth factor and nucleic acids encoding same

Also Published As

Publication number Publication date
CA2388637A1 (en) 2001-05-03
WO2001031008A2 (en) 2001-05-03
EP1224283A2 (en) 2002-07-24
JP2003512841A (ja) 2003-04-08
WO2001031008A3 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
AU6069300A (en) Novel human genes and gene expression products
AU4053699A (en) Novel human genes and gene expression products
AU4187499A (en) Human genes and gene expression products v
AU2001249125A1 (en) Human fgf-23 gene and gene expression products
AU2095599A (en) Human genes and gene expression products i
AU5440901A (en) Cosmetic and/or pharmaceutical preparations
AU6503299A (en) High-beta-conglycinin products and their use
AU2001245619A1 (en) Human genes and gene expression products
AU2001285047A1 (en) Human genes and gene expression products
AU2001245535A1 (en) Human fgf-23 gene and gene expression products
AU4117000A (en) Cosmetic product and its use
AU4329300A (en) Human mesenchymal dnas and expression products
GB9928490D0 (en) Products and processes therefor
AU2438400A (en) Cosmetic and/or pharmaceutical preparations
AU6263400A (en) Polyisocyanate-polyaddition products
AU4293800A (en) Cosmetic and/or pharmaceutical preparations
AU2067501A (en) Human oxidoreductase proteins
AU6263999A (en) Human genes and gene expression products
GB9919338D0 (en) Biological products
AU2001262934A1 (en) Human fgf-20 nucleic acids and polypeptides
AU2001287269A1 (en) Human genes and expression products
AU4402600A (en) Fat containing products
AU5088600A (en) Gene therapy products
AU3900000A (en) Human fgf gene and gene expression products
AU4834799A (en) Human az-1 gene, variants thereof and expressed gene products

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase